Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel Free CINGW Stock Alerts

Cingulate (CINGW) Competitors

$0.0091 0.00 (-22.88%)
As of 08/21/2026 03:52 PM Eastern
Compare

CINGW vs. SXTPW, BFRIW, CALA, CMRAW, and CDTTW

Should you buy Cingulate stock or one of its competitors? Cingulate's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Comera Life Sciences (CMRAW), and Conduit Pharmaceuticals (CDTTW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cingulate compare to 60 Degrees Pharmaceuticals?

Cingulate (NASDAQ:CINGW) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

In the previous week, Cingulate's average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cingulate Neutral
60 Degrees Pharmaceuticals Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats Cingulate on 1 of the 1 factors compared between the two stocks.

How does Cingulate compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Biofrontera's average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company Overall Sentiment
Biofrontera Neutral
Cingulate Neutral

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Cingulate N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Summary

Biofrontera beats Cingulate on 1 of the 1 factors compared between the two stocks.

How does Cingulate compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Cingulate N/A N/A N/A

In the previous week, Calithera Biosciences had 1 more articles in the media than Cingulate. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Cingulate. Calithera Biosciences' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Cingulate Neutral

Summary

Calithera Biosciences beats Cingulate on 1 of the 1 factors compared between the two stocks.

How does Cingulate compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Cingulate Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Cingulate N/A N/A N/A

Summary

Comera Life Sciences beats Cingulate on 1 of the 1 factors compared between the two stocks.

How does Cingulate compare to Conduit Pharmaceuticals?

Cingulate (NASDAQ:CINGW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Company Net Margins Return on Equity Return on Assets
CingulateN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

In the previous week, Cingulate's average media sentiment score of 0.00 equaled Conduit Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cingulate Neutral
Conduit Pharmaceuticals Neutral

Summary

Cingulate and Conduit Pharmaceuticals tied by winning 0 of the 0 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Sign up to receive the latest news and ratings for CINGW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CINGW vs. The Competition

Export
MetricCingulatePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.51B$7.36B$12.84B
Dividend YieldN/A2.61%2.54%11.08%
P/E RatioN/A789.80272.8824.24
Price / SalesN/A768.11622.1799.48
Price / CashN/A96.7778.6253.99
Price / BookN/A11.8913.056.20
Net IncomeN/A$2.81B$3.47B$348.59M
7 Day PerformanceN/A1.77%2.09%0.08%
1 Month PerformanceN/A3.85%6.64%3.88%
1 Year PerformanceN/A6.56%25.02%16.98%

Cingulate Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CINGW
Cingulate
N/A$0.01
-22.9%		N/A-81.8%$0.00N/AN/A20
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
+7.3%		N/A-67.6%$0.00$1.00MN/A2
BFRIW
Biofrontera
N/A$0.03
+17.7%		N/A-69.8%$0.00$43.20MN/A70
CALA
Calithera Biosciences
N/AN/AN/AN/A$0.00N/AN/A60
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CINGW) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel